clofibrate has been researched along with niceritrol in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Carlson, LA; Olsson, AG; Orö, L; Rössner, S | 1 |
| Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B | 1 |
| Hansen, PF | 1 |
| Itakura, H | 1 |
| Boberg, J; Gustafsson, IB; Lithell, H; Vessby, B | 1 |
| Hellsing, K; Lithell, H; Vessby, B | 1 |
| Fujioka, T; Matsumoto, T; Ueno, T; Watanabe, H | 1 |
1 review(s) available for clofibrate and niceritrol
| Article | Year |
|---|---|
[Dyslipidemia in renal failure].
Topics: Arteriosclerosis; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronary Disease; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lipoproteins, VLDL; Niceritrol; Peripheral Vascular Diseases; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis; Triglycerides | 2004 |
1 trial(s) available for clofibrate and niceritrol
| Article | Year |
|---|---|
Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
Topics: Aged; Cholesterol Esters; Clinical Trials as Topic; Clofibrate; Diet Therapy; Dose-Response Relationship, Drug; Fatty Acids; Female; Follow-Up Studies; Humans; Linoleic Acids; Male; Middle Aged; Myocardial Infarction; Niceritrol; Nicotinic Acids; Phospholipids; Triglycerides | 1980 |
6 other study(ies) available for clofibrate and niceritrol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
Topics: Cholestyramine Resin; Clofibrate; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, LDL; Lipoproteins, VLDL; Niceritrol; Nicotinic Acids; Triglycerides | 1975 |
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niceritrol; Nicotinic Acids | 1979 |
Differential drug therapy of the hyperlipoproteinaemias. The efficacy of lipid lowering drugs alone and in combination.
Topics: Cholesterol; Clofibrate; Drug Synergism; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Niceritrol; Triglycerides | 1975 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dietary Fiber; Energy Intake; Female; Humans; Hyperlipidemias; Male; Niceritrol; Pravastatin; Probucol | 1992 |
Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
Topics: Aged; Arteriosclerosis; Blood Glucose; Body Weight; Clofibrate; Dietary Carbohydrates; Female; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Male; Middle Aged; Niceritrol | 1982 |